| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/23/2013 | US20130130981 Treatment using neublastin polypeptides |
| 05/23/2013 | US20130130977 Polymer-based sustained release device |
| 05/23/2013 | US20130130974 NOVEL SYNTHETIC APPROACH TO beta-AMINOBUTYRYL SUBSTITUTED COMPOUNDS |
| 05/23/2013 | US20130130971 Method for Inhibiting HIV Replication in Mammal and Human Cells |
| 05/23/2013 | US20130130968 Compounds for enzyme inhibition |
| 05/23/2013 | US20130130247 Kits and Methods for Assessing Skin Health |
| 05/23/2013 | US20130129975 Medical or biochemical resin composition and resin molded product |
| 05/23/2013 | US20130129844 Preservative-Free Composition for Topical Use Including Hyaluronic Acid |
| 05/23/2013 | US20130129841 Therapeutic combination comprising a parp-1 inhibitor and an anti-neoplastic agent |
| 05/23/2013 | US20130129840 Combination therapy using a ruthenium complex |
| 05/23/2013 | US20130129832 Cognitive impairment ameliorant |
| 05/23/2013 | US20130129824 Solid Drug Tablets for Implantable Drug Delivery Devices |
| 05/23/2013 | US20130129822 Liquid-filled hard gel capsule pharmaceutical formulations |
| 05/23/2013 | US20130129820 Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| 05/23/2013 | US20130129819 Pharmaceutical Formulations Containing An SGLT2 Inhibitor |
| 05/23/2013 | US20130129818 Natural combination hormone replacement formulations and therapies |
| 05/23/2013 | US20130129809 Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells |
| 05/23/2013 | US20130129808 Medical product containing active component of propolis or grapefruit seed extract and manufacturing method thereof |
| 05/23/2013 | US20130129801 Aqueous dispersion comprising galactolipids and method for production thereof |
| 05/23/2013 | US20130129795 Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives |
| 05/23/2013 | US20130129792 Pharmacokinetics of S-Adenosylmethionine Formulations |
| 05/23/2013 | US20130129789 Anti-bacterial applications of poly-n-acetylglucosamine nanofibers |
| 05/23/2013 | US20130129785 Methods and compositions for delivery of active agents |
| 05/23/2013 | US20130129784 Methods of inhibition of protein fucosylation in vivo using fucose analogs |
| 05/23/2013 | US20130129773 Anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof |
| 05/23/2013 | US20130129772 Ameliorative or preventive effect of antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death |
| 05/23/2013 | US20130129749 Humanized anti-egfl7 antibodies and methods using same |
| 05/23/2013 | US20130129742 Human leukolectins and uses thereof |
| 05/23/2013 | US20130129733 Humanized anti-egfl7 antibodies and methods using same |
| 05/23/2013 | US20130129720 Combination Cancer Therapies with Wortmannin Analogs |
| 05/23/2013 | US20130129719 Her2 nucleic acid aptamers |
| 05/23/2013 | US20130129695 Methods for treating or inhibiting infection by clostridium difficile |
| 05/23/2013 | US20130129680 Method for treating hepatitis c virus infection using quercetin-containing compositions |
| 05/23/2013 | US20130129678 Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer |
| 05/23/2013 | US20130129677 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
| 05/23/2013 | US20130129676 Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection |
| 05/23/2013 | US20130129675 Interferon therapies in combination with blockade of stat3 activation |
| 05/23/2013 | US20130129665 Cyclodextrin-based polymers for therapeutics delivery |
| 05/23/2013 | US20130129662 Compositions and Methods for the Treatment of Heart Failure |
| 05/23/2013 | US20130129661 Material for skin and method for producing material for skin |
| 05/23/2013 | US20130129660 Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders |
| 05/23/2013 | US20130129659 Composite enterosorbent |
| 05/23/2013 | US20130129643 Oral care compositions |
| 05/23/2013 | US20130129639 Cassia Derivatives |
| 05/23/2013 | US20130129638 Use of Glyceryl Trinitrate for Treating Traumatic Edema |
| 05/23/2013 | US20130129617 Method for Treating Psoriatic Arthritis By Administering An Anti-IL-12 Antibody |
| 05/23/2013 | US20130129615 Methods, compositions and kits for providing a therapeutic treatment |
| 05/23/2013 | US20130125887 Crystalline forms of a biphenyl compound |
| 05/23/2013 | US20130125882 Method and composition for treating asthma and copd |
| 05/23/2013 | DE102012109727A1 Enterosorbenszusammensetzung Enterosorbenszusammensetzung |
| 05/23/2013 | CA2856291A1 Inhibitors of c-jun-n-terminal kinase (jnk) |
| 05/23/2013 | CA2856289A1 Modified rnai agents |
| 05/23/2013 | CA2856288A1 Nucleic acid fragment binding to target protein |
| 05/23/2013 | CA2856243A1 Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| 05/23/2013 | CA2856229A1 Methods of treatment with deferiprone |
| 05/23/2013 | CA2856217A1 Apocynin-lipoic acid conjugates and uses thereof |
| 05/23/2013 | CA2856116A1 Therapeutic rna switches compositions and methods of use |
| 05/23/2013 | CA2856103A1 Morpholinyl benzotriazine for use in cancer therapy |
| 05/23/2013 | CA2856100A1 Nitrogen-containing fused ring compounds as crth2 antagonists |
| 05/23/2013 | CA2856076A1 Muscarinic m1 receptor agonists |
| 05/23/2013 | CA2856030A1 Bisphosphonate compositions and methods for treating and/or reducing cardiac dysfunction |
| 05/23/2013 | CA2856016A1 Agent for treating fibrosis of the intestine |
| 05/23/2013 | CA2855954A1 Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof |
| 05/23/2013 | CA2855950A1 Kinase modulating compounds, compositions containing the same and use thereof |
| 05/23/2013 | CA2855837A1 Methods for treating leishmaniasis |
| 05/23/2013 | CA2855759A1 Tricyclic compounds, compositions comprising them and uses thereof |
| 05/23/2013 | CA2855718A1 Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
| 05/23/2013 | CA2855619A1 Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2 - signal transducer and activator of transcription 5 pathway |
| 05/23/2013 | CA2855545A1 Oral leptin formulations and uses thereof |
| 05/23/2013 | CA2855346A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors |
| 05/23/2013 | CA2854946A1 Apricitabine and pi combination therapy |
| 05/23/2013 | CA2854717A1 Treatment of adrenal insufficiency |
| 05/23/2013 | CA2854188A1 Combination therapy of hsp90 inhibitors with braf inhibitors |
| 05/23/2013 | CA2853254A1 N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 05/23/2013 | CA2852697A1 Uracil derivatives as axl and c-met kinase inhibitors |
| 05/23/2013 | CA2851209A1 Pharmaceutical solid compositions containing ibuprofen salts |
| 05/23/2013 | CA2851151A1 Aminoquinazoline derivatives and their salts and methods of use |
| 05/23/2013 | CA2850584A1 1-pyridazinyl-hydroxyimino-3-phenyl-propanes as gpbar1 agonists |
| 05/23/2013 | CA2815082A1 Antiviral compounds |
| 05/22/2013 | EP2594644A1 Method for preparing novel hipsc by means of mirna introduction |
| 05/22/2013 | EP2594643A1 Method for producing novel hipsc by means of sirna introduction |
| 05/22/2013 | EP2594642A1 Induction of exon skipping in eukaryotic cells |
| 05/22/2013 | EP2594641A1 Induction of exon skipping in eukaryotic cells |
| 05/22/2013 | EP2594640A1 Induction of exon skipping in eukaryotic cells |
| 05/22/2013 | EP2594592A1 (nucleic acid)-polysaccharide complex |
| 05/22/2013 | EP2594575A1 Mannosylated compounds useful for the prevention and the treatment of infectious diseases |
| 05/22/2013 | EP2594570A1 Crystal of thienopyrimidine derivative |
| 05/22/2013 | EP2594568A1 Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes |
| 05/22/2013 | EP2594567A1 Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof |
| 05/22/2013 | EP2594566A1 Nitrogenated aromatic heterocyclic ring derivative |
| 05/22/2013 | EP2594565A2 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| 05/22/2013 | EP2594564A2 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| 05/22/2013 | EP2594563A2 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| 05/22/2013 | EP2594562A2 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| 05/22/2013 | EP2594561A1 Structural variants of mycolactones for use in modulating inflammation, immunity and pain |
| 05/22/2013 | EP2594559A1 Pyrazole compound |
| 05/22/2013 | EP2594557A1 Substituted aminopropionic derivatives as neprilysin inhibitors |
| 05/22/2013 | EP2594556A1 Substituted aminopropionic derivatives as neprilysin inhibitors |
| 05/22/2013 | EP2594555A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR |
| 05/22/2013 | EP2594554A1 Biaryl amide derivative or pharmaceutically acceptable salt thereof |